San Diego, USA-based clinical-stage cell and gene therapy company Poseida Therapeutics (Nasdaq: PSTX) saw its shares close up more than 20% at $2.92 yesterday, when it revealed a second collaboration with Japanese drug major Astellas Pharma (TYO: 4503).

Astellas wholly-owned Xyphos Bioscience and Poseidahave entered into a research collaboration and license agreement to develop novel convertible CAR programs by combining the innovative cell

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

Original post:
Astellas and Poseida enter second research collaboration - The Pharma Letter

Comments are closed.